Navigation Links
DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations

IRVING, Texas, Officials of DelSite Biotechnologies, Inc., a wholly-owned subsidiary of Carrington Laboratories, Inc. said the company's novel powder-based vaccine delivery technology may solve most of the key obstacles that delay influenza pandemic preparedness which were discussed by experts at the worldwide "Options for the Control of Influenza VI Conference" held in Toronto, Canada last week.

Long-standing problems associated with the production, storage and distribution of vaccines to meet the challenges posed by a pandemic outbreak of an influenza virus, such as the bird flu (H5N1), were highlighted in a series of presentations at the conference. The Conference was supported by the U.S. Center for Disease Control (CDC) and the International Society for Influenza and other Respiratory Virus Diseases (ISIRV).

More than 1,500 influenza experts from around the world attended the conference, including government policy makers, pharmaceutical executives, researchers, physicians, epidemiologists and other professionals focused on the control of influenza.

The following key needs were cited:

1. The ability to have an adequate stockpile of vaccines. Current vaccines must be refrigerated during storage and distribution. Despite its cost and inconvenience, cold storage does not significantly extend the short shelf life of influenza antigens and vaccines. DelSite's GelVac(TM) powder vaccine system has been shown to stabilize and preserve an influenza antigen at room temperature for more than two (2) years without loss of potency.

2. The capability to implement rapid distribution in the event of a full pandemic. According to one flu expert, if the next influenza pandemic is equivalent to the flu pandemic that occurred in 1957 (H2N2 virus), timing of actions by the U.S. government would be critical. In 1957, under transportation systems available at the time, it took only six months for the virus to trav
'"/>




Page: 1 2 3

Related medicine news :

1. Working in shifts may cause damage to your health
2. Junior Doctors Working Long Hours May Perform Poorly
3. New UK Policy Threatens The Flexible Working Scheme
4. Medicare Drug Plan Is Not Working in The US
5. Warning! Working For Long Hours On Your Computer Can Be Lethal
6. Stressed Pregnant Working Mothers Put Their Unborn Child’s Life in Dange
7. Working of Drug Department on Hold Without Drug Analyst
8. Doctor Faces Disbarment For Working In Multiple Hospitals
9. Computational Model Reveals Working of AZT in Body
10. Scientists Working On Drug Trial Guidelines
11. Scientists Uncover Complex Workings of Sperm
Post Your Comments:
(Date:7/3/2009)... ReverseAges.com launches new content ...adrenal fatigue, and how to best deal with these h..., CA (PRWEB) July 3, 2009 -- ReverseAges.com has r...s explain the dangers of common health issues such...used by a variety of factors, and the new content ...
(Date:7/2/2009)...at Singapore,s Bioprocessing Technology Institute ...ne, "Fas-apoptosis inhibitory molecule" (FAIM), pr... or programmed cell death. , Their research is ...ifferentiation . , The scientists, Jianxin Huo, ... this process may possibly be manipulated for clin...
(Date:7/2/2009)...LVER, N.J., July 2 Dr Daniel Goldb...inating a new study to measure the effectiveness o...ute EKC -- a common, worldwide, highly contagious ...otential for long term visual impairment due to co...the world are invited to register to participate i...
(Date:7/2/2009)...p aid shuts down one set of neurons, another set w...althDay News) -- New information about brain circu...ake the sleep aid Ambien (zolpidem) walk, eat, tal...e -- and without remembering it the next morning. ...lly conscious patients into a conscious state. ,...
Breaking Medicine News(10 mins):Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2Health News:Odd Behaviors on Ambien Linked to Brain Circuitry 2
...can surgeon, who immigrated from Madhya Pradesh, h...rd by the New York Eye and Ear Infirmary.// Navin...same Infirmary, will be presented the 2006 John Ke...the Year Award on Nov 20 in New York. Mehta gradua...
...ich was the biggest killer disease in the UK durin...ver 10% from 2004 to 2005. //Th number of cases ha...been the single largest leap , causing great conce... disease which killed several famous poets like Jo...
...e more susceptible to strep throat infection benef... clinic study.// Children whose tonsils have not ...evelop subsequent episodes of strep throat than ch...y. . "These results suggest that tonsillectomy is ...
...more people came down with acute symptoms of dengu...the toll of infected people// to an alarming figur...th the latest casualty being a person from Peshawa...NIH) has reiterated via a press release that sampl...
Other Medicine News:Health News:TB Returns , Sharp Rise In Cases In UK 2Health News:Tonsillectomy reduces risk of strep throat 2
(Date:6/30/2009)...., June 30 In two recent COPD stud...and PRONEB compressors (Ultra and Ultra II) were u...rforomist, DEY LP, Mylan Inc.) improves pulmonary ... chose PARI products as the exclusive nebulizer sy...atments for COPD. Sutherland et al. used an open-...
(Date:6/29/2009)...udy Seeks to Assess RSV Burden in Outpatient Setti...nt to Pediatric Research , , GAITHERSBURG, Md...advance its commitment to pediatric research with ...ospective study designed to assess the burden of r...ants 32-to-35 weeks gestational age (GA) in outpat...
(Date:6/28/2009)...f., June 29 Sangamo BioS...at a key research milestone has been achieved in i...Inc., a wholly-owned member of the Roche Group, fo...ristics for pharmaceutical protein production purp...inding protein nuclease (ZFN) technology. Genentec...
(Date:6/26/2009)...s release, "Agendia,s Breast Cancer Recurrence Tes... Expert Consensus Recommendations" issued,on 23 J...e, please be advised,that the subheadline was mis...by PR Newswire. Complete, corrected release follow...s Breast Cancer Recurrence Test MammaPrint Include...
Breaking Medicine Technology:PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3Epsilon Securities LLC to Provide M 26A Advisory Services to MEDdevice Acquisition Co LLC 18774 1Met Pro Corporation to Report First Quarter Earnings on May 22 18772 1Met Pro Corporation to Report First Quarter Earnings on May 22 18772 2Met Pro Corporation to Report First Quarter Earnings on May 22 18772 3Reaching a Milestone 3A Project Smile Makes Local Charities and Patients Smile 18770 1Phyhealth Signs Agreement with Argus Dental to Provide Dental Services for Pilot HMO 18768 1Phyhealth Signs Agreement with Argus Dental to Provide Dental Services for Pilot HMO 18768 2
...INESS WIRE)--Apr 23, 2007 - Affymax, Inc.,(Nasdaq:...arate,Phase 2 clinical trials of Hematide(TM) in d...KD) patients. The data showed,that in treatment na...anemia when administered monthly at an appropriate...eviously treated with,three-times weekly Epoetin A...
...WIRE)--Apr 23, 2007 - CytRx Corporation,(NASDAQ:CY...i),delivery technology exclusively licensed to its...rporation (RXi), has been,published in the April 2...Chemical Biology. The technology was developed by ...nd University of,Massachusetts Medical School (UMM...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: